Palisade Bio (NASDAQ:PALI) Announces Earnings Results, Beats Expectations By $1.70 EPS

Palisade Bio (NASDAQ:PALI) released its quarterly earnings results on Monday. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.39) by $1.70, Zacks reports.

Palisade Bio Stock Performance

Shares of NASDAQ:PALI opened at $0.69 on Wednesday. Palisade Bio has a twelve month low of $0.66 and a twelve month high of $9.65. The firm has a market cap of $1.91 million, a PE ratio of -0.05 and a beta of 1.49. The business has a fifty day moving average of $1.10 and a 200-day moving average of $2.15.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.